EPRX
Eupraxia·NASDAQ
--
--(--)
--
--(--)
EPRX fundamentals
During Q4 2025, Eupraxia (EPRX) reported revenue of --, a YoY change of 0.00%. Net income was -16.72M, a YoY change of -121.99%. Click to view the full income statement and explore the company's earnings performance.
Income Statement
Q3,2022 | Q4,2022 | Q1,2023 | Q2,2023 | Q3,2023 | Q4,2023 | Q1,2024 | Q2,2024 | Q3,2024 | Q4,2024 | Q1,2025 | Q2,2025 | Q3,2025 | Q4,2025 | TTM |
|---|
Start Date | Jul 1, 2022 | Oct 1, 2022 | Jan 1, 2023 | Apr 1, 2023 | Jul 1, 2023 | Oct 1, 2023 | Jan 1, 2024 | Apr 1, 2024 | Jul 1, 2024 | Oct 1, 2024 | Jan 1, 2025 | Apr 1, 2025 | Jul 1, 2025 | Oct 1, 2025 | -- |
End Date | Sep 30, 2022 | Dec 31, 2022 | Mar 31, 2023 | Jun 30, 2023 | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | -- |
Fiscal Year-End | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | -- |
Revenue | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Cost of Revenue | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Operating Expenses | 3.52M -- | 6.49M -- | 3.54M -- | 5.71M -- | 6.62M +87.99% | 11.98M +84.71% | 6.69M +89.27% | 6.56M +14.81% | 6.27M -5.28% | 7.48M -37.54% | 7.12M +6.44% | 8.26M +26.07% | 6.88M +9.72% | 16.16M +116.03% | 38.43M -- |
Selling, General and Administrative Expenses | 721.80K -- | 290.69K -- | 1.26M -- | 1.92M -- | 1.86M +158.21% | 2.44M +737.98% | 2.52M +99.55% | 2.58M +34.36% | 2.22M +19.29% | 3.60M +47.77% | 3.27M +30.04% | 3.07M +18.75% | 2.47M +10.89% | 8.30M +130.44% | 17.10M -- |
General and Administrative Expenses | -- -- | 2.80M -- | -- -- | -- -- | 1.86M -- | 2.44M -12.97% | 2.52M -- | 2.58M -- | 2.22M +19.29% | 3.60M +47.77% | 3.27M +30.04% | 3.07M +18.75% | 2.47M +10.89% | 8.30M +130.44% | 17.10M -- |
Research and Development Expenses | 2.80M -- | 4.80M -- | 2.27M -- | 3.79M -- | 4.76M +69.90% | 9.54M +98.83% | 4.18M +83.57% | 3.97M +4.88% | 4.05M -14.90% | 3.88M -59.32% | 3.85M -7.80% | 5.20M +30.83% | 4.42M +9.08% | 7.87M +102.67% | 21.33M -- |
Other Operating Expenses | -- -- | 1.40M -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Operating Income | -3.52M -- | -6.49M -- | -3.54M -- | -5.71M -- | -6.62M -87.99% | -11.98M -84.71% | -6.69M -89.27% | -6.56M -14.81% | -6.27M +5.28% | -7.48M +37.54% | -7.12M -6.44% | -8.26M -26.07% | -6.88M -9.72% | -16.16M -116.03% | -38.43M -- |
Non-Operating Income (Loss) | -396.09K -- | -1.31M -- | -419.63K -- | -3.80M -- | 1.73M +535.92% | 1.41M +207.52% | 541.54K +229.05% | 486.21K +112.81% | 281.90K -83.67% | -48.92K -103.48% | 359.74K -33.57% | -478.00K -198.31% | 513.12K +82.02% | -547.38K -1018.81% | -152.52K -- |
Gain (Loss) on Change in Fair Value | -- -- | -1.09M -- | -- -- | -- -- | 1.88M -- | 1.25M +215.19% | 770.04K -- | 430.50K -- | 0 -100.00% | 0 -100.00% | 0 -100.00% | 0 -100.00% | 0 -- | 0 -- | -- -- |
Gain (Loss) on Foreign Currency Exchange | -- -- | 232.14K -- | -- -- | -- -- | -25.96K -- | 59.28K -74.46% | -143.73K -- | -75.04K -- | -21.99K +15.31% | 81.55K +37.56% | 51.36K +135.74% | -733.96K -878.08% | 332.93K +1614.02% | -1.21M -1587.29% | -1.56M -- |
Other Non-Operating Income (Loss) | -287.55K -- | -340.81K -- | -291.19K -- | -3.65M -- | 0 +100.00% | -188 +99.94% | 0 +100.00% | 11.37K +100.31% | 0 -- | -348.34K -185186.70% | -1.07K -- | 0 -100.00% | 0 -- | -1.49K +99.57% | -2.56K -- |
Net Interest Expense | 108.53K -- | 114.27K -- | 128.44K -- | 149.50K -- | 126.59K +16.64% | -97.33K -185.17% | 84.77K -34.00% | -119.38K -179.85% | -303.89K -340.06% | -217.87K -123.85% | -309.45K -465.04% | -255.96K -114.40% | -180.19K +40.71% | -666.92K -206.11% | -1.41M -- |
Interest Expense | 248.58K -- | 282.24K -- | 291.48K -- | 301.77K -- | 320.47K +28.92% | 256.46K -9.13% | 321.14K +10.18% | 281.85K -6.60% | 451 -99.86% | 137 -99.95% | 0 -100.00% | 0 -100.00% | 0 -100.00% | 0 -100.00% | -- -- |
Interest Income | 140.04K -- | 167.97K -- | 163.03K -- | 152.27K -- | 193.88K +38.44% | 353.79K +110.63% | 236.37K +44.98% | 401.23K +163.49% | 304.34K +56.98% | 218.01K -38.38% | 309.45K +30.92% | 255.96K -36.21% | 180.19K -40.80% | 666.92K +205.92% | 1.41M -- |
Pretax Income From Continuing Operations | -3.92M -- | -7.79M -- | -3.96M -- | -9.51M -- | -4.90M -24.93% | -10.57M -35.63% | -6.15M -55.51% | -6.07M +36.16% | -5.99M -22.37% | -7.53M +28.76% | -6.76M -9.96% | -8.74M -44.05% | -6.37M -6.32% | -16.71M -121.90% | -38.59M -- |
Income Tax Expense | -- -- | 0 -- | -- -- | -- -- | -- -- | 36.42K -- | 5.00K -- | -5.00K -- | 0 -- | 1.80K -95.05% | 2.79K -44.12% | 5.58K +211.62% | -623 -- | 11.34K +528.55% | 19.09K -- |
Current Income Tax | -- -- | -- -- | -- -- | -- -- | -- -- | 36.42K -- | -- -- | -- -- | -- -- | 1.80K -95.05% | -- -- | -- -- | -- -- | 19.09K +958.26% | -- -- |
Deferred Income Tax | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- |
Net Income | -3.92M -- | -7.79M -- | -3.96M -- | -9.51M -- | -4.90M -24.93% | -10.61M -36.10% | -6.16M -55.63% | -6.06M +36.21% | -5.99M -22.37% | -7.53M +28.99% | -6.77M -9.91% | -8.75M -44.26% | -6.37M -6.31% | -16.72M -121.99% | -38.61M -- |
Net Income Attributable to Minority Interests | -101.24K -- | -192.30K -- | -60.70K -- | -129.38K -- | -174.74K -72.61% | -380.39K -97.81% | -113.89K -87.65% | -56.68K +56.19% | -47.99K +72.53% | -23.39K +93.85% | -4.67K +95.90% | -6.77K +88.06% | -7.99K +83.35% | -10.08K +56.88% | -29.51K -- |
Net Income Attributable to Owners of the Company | -3.82M -- | -7.60M -- | -3.90M -- | -9.38M -- | -4.72M -23.67% | -10.23M -34.54% | -6.04M -55.13% | -6.01M +35.94% | -5.94M -25.88% | -7.51M +26.58% | -6.76M -11.91% | -8.74M -45.51% | -6.36M -7.03% | -16.71M -122.55% | -38.58M -- |
Net Income Attributable to Common Stockholders | -3.82M -- | -7.60M -- | -3.90M -- | -9.38M -- | -4.72M -23.67% | -10.23M -34.54% | -6.04M -55.13% | -6.01M +35.94% | -5.94M -25.88% | -7.51M +26.58% | -6.76M -11.91% | -8.74M -45.51% | -6.36M -7.03% | -16.71M -122.55% | -38.58M -- |
Other Comprehensive Income | -- -- | 0 -- | -5.52K -- | -15.55K -- | 90.54K -- | 10.35K -- | -32.39K -486.71% | -180.21K -1058.66% | 124.43K +37.44% | -1.37M -13296.48% | 38.16K +217.82% | 1.34M +840.83% | -508.63K -508.77% | 1.25M +191.66% | 2.12M -- |
Total Comprehensive Income | -3.92M -- | -7.79M -- | -3.96M -- | -9.52M -- | -4.81M -22.62% | -10.60M -35.96% | -6.19M -56.23% | -6.24M +34.42% | -5.87M -22.09% | -8.90M +16.03% | -6.73M -8.72% | -7.41M -18.71% | -6.88M -17.23% | -15.47M -73.85% | -36.49M -- |
Total Comprehensive Income Attributable to Owners of the Company | -3.92M -- | -7.79M -- | -3.96M -- | -9.52M -- | -4.81M -22.62% | -10.60M -35.96% | -6.19M -56.23% | -6.24M +34.42% | -5.87M -22.09% | -8.90M +16.03% | -6.73M -8.72% | -7.41M -18.71% | -6.88M -17.23% | -15.47M -73.85% | -36.49M -- |
Basic EPS | -0.18 -- | -- -- | -0.18 -- | -0.43 -- | -0.18 -- | -- -- | -0.21 -16.67% | -0.17 +60.47% | -0.17 +5.56% | -0.21 -- | -0.21 -- | -0.26 -52.94% | -0.19 -11.76% | -0.32 -52.38% | -0.98 -- |
Basic EPS from Continuing Operations | -- -- | -- -- | -- -- | -- -- | -0.18 -- | -- -- | -0.21 -- | -0.17 -- | -0.17 +5.56% | -- -- | -0.21 -- | -0.26 -52.94% | -0.19 -11.76% | -- -- | -- -- |
Diluted EPS | -0.18 -- | -- -- | -0.18 -- | -0.43 -- | -0.18 -- | -- -- | -0.21 -16.67% | -0.17 +60.47% | -0.17 +5.56% | -- -- | -0.21 -- | -0.26 -52.94% | -0.19 -11.76% | -- -- | -- -- |
Diluted EPS from Continuing Operations | -- -- | -- -- | -- -- | -- -- | -0.18 -- | -- -- | -0.21 -- | -0.17 -- | -0.17 +5.56% | -- -- | -0.21 -- | -0.26 -52.94% | -0.19 -11.76% | -- -- | -- -- |
You can ask Aime
What does Eupraxia do and what are its main business segments?Did Eupraxia beat or miss consensus estimates last quarter?What factors drove the changes in Eupraxia's revenue and profit?What is Eupraxia's latest dividend and current dividend yield?What were the key takeaways from Eupraxia’s earnings call?What is the market's earnings forecast for Eupraxia next quarter?What is the revenue and EPS growth rate for Eupraxia year over year?What is Eupraxia's gross profit margin?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
